Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting

Rhea-AI Summary

Neoleukin Therapeutics (NASDAQ:NLTX) announced an oral presentation at the American Society of Hematology (ASH) Annual Meeting scheduled for December 10-13, 2022, in New Orleans. The presentation titled NEO-TRA1 will focus on a CD25-targeted de novo non-Alpha Agonist of the IL-2 receptor, which selectively expands regulatory T cells. The session will take place on December 12, 2022, at 11:45 AM at the Ernest N. Morial Convention Center.

Neoleukin aims to innovate immunotherapies for cancer and autoimmune diseases through advanced protein design technology.

Positive

• Scheduled an oral presentation at the ASH Annual Meeting, indicating active engagement in the scientific community.
• Focus on innovative therapeutics, potentially enhancing investor confidence.

Negative

• None.

SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced an oral presentation at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 10-13, 2022 in New Orleans, Louisiana.

Oral presentation details are as follows:

Title:  NEO-TRA1: A CD25-Targeted De Novo non-Alpha Agonist of the IL-2 Receptor Selectively Expands Regulatory T Cells
Session Name: 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Delineating Immunity from Mice to Humans 
Publication Number: 684
Session Date/Time: Monday, December 12, 2022, 11:45 AM
Location: Ernest N. Morial Convention Center, 278-282

About Neoleukin Therapeutics, Inc.

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com.

Contacts:
Media
Julie Rathbun
206-769-9219
jrathbun@neoleukin.com

Investors
Solebury Trout
Alexandra Roy
617-221-9197
aroy@soleburytrout.com

FAQ

What is the significance of Neoleukin's presentation at the ASH Annual Meeting?

Neoleukin's presentation highlights the company's commitment to advancing immunotherapy research, showcasing their innovative protein therapeutics.

When is Neoleukin's presentation scheduled at ASH 2022?

The presentation is scheduled for December 12, 2022, at 11:45 AM.

What is the focus of Neoleukin's oral presentation?

The presentation focuses on a CD25-targeted de novo non-Alpha Agonist of the IL-2 receptor that selectively expands regulatory T cells.

Where will Neoleukin's presentation take place?

The presentation will be held at the Ernest N. Morial Convention Center in New Orleans.

What is Neoleukin's lead product candidate?

Neoleukin's lead product candidate is NL-201, designed to be a combined IL-2 and IL-15 agonist for enhanced tolerability and activity.